Investigating the Impact of Advertising on Smoking Cessation: The Role of Direct-to-Consumer Prescription Drug Advertising.

This article investigates the effects of direct-to-consumer advertising (DTCA) for smoking cessation prescription drugs, particularly Varenicline (Chantix), on consumer behavior and cigarette consumption, while examining how access barriers such as insurance coverage and healthcare provider availability moderate these effects. Using a comprehensive dataset combining prescription records, retail sales, and advertising exposure from 2011 to 2019, the study finds that DTCA for prescription drugs significantly reduces cigarette demand and increases prescriptions for both Chantix and Bupropion, with spillover effects to e-cigarettes but not consistently to over-the-counter (OTC) nicotine replacement therapies (NRTs). In contrast, advertising for OTC NRTs tends to divert consumers away from more effective prescription options without reducing cigarette consumption. The effectiveness of prescription drug advertising is enhanced in regions with higher insurance coverage and better access to healthcare providers, which reduces substitution toward OTC alternatives. These findings suggest that DTCA for smoking cessation prescription drugs can positively impact public health by lowering cigarette use, challenging calls for blanket bans on such advertising, and highlighting the importance of institutional factors in shaping advertising outcomes.